

76

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau







INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07C 275/28, C07D 213/75, 257/04, 231/12, 401/12, A61K 31/17, 31/44, 31/41, C07D 213/40, 307/38, 277/28, 233/54, C07C 311/21, C07D 333/20		A1	(11) International Publication Number: <b>WO 96/10559</b>
(21) International Application Number: PCT/JP95/01982		(43) International Publication Date: 11 April 1996 (11.04.96)	
(22) International Filing Date: 29 September 1995 (29.09.95)		(74) Agent: SEKI, Hideo; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532 (JP).	
(30) Priority Data: 9419970.0 4 October 1994 (04.10.94) GB 9506720.3 31 March 1995 (31.03.95) GB 9514021.6 10 July 1995 (10.07.95) GB		(81) Designated States: AU, CA, CN, HU, JP, KR, MX, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. (JP/JP); 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP).		<p><b>Published</b></p> <p>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
(72) Inventors; and (75) Inventors/Applicants (for US only): TERASAWA, Takeshi (JP/JP); 1625-302, Matsugaokanakamachi, Kawachinagano- shi, Osaka 586 (JP). TANAKA, Akira (JP/JP); 9-10-302, Nakano-cho, Takarazuka-shi, Hyogo 665 (JP). CHIBA, Toshiyuki (JP/JP); 1-1-503, Nakatsuji-cho, Nara-shi, Nara 630 (JP). TAKASUGI, Hisashi (JP/JP); 3-116-10, Mozu Umekita, Sakai-shi, Osaka 591 (JP).			

(54) Title: UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS

(57) Abstract

Urea derivatives of formula (I), wherein R<sup>1</sup> is a group of formula (1) (in which R<sup>4</sup> is aryl which may have suitable substituent(s), or heterocyclic group which may have suitable substituent(s), and Y is bond, lower alkylene, -S-, -O-, (a), -CH-, -CONH-, (b), (in which R<sup>7</sup> is lower alkyl), -NHCO-, -SO<sub>2</sub>NH-, -SO<sub>2</sub>NHCO- or -CONHSO<sub>2</sub>-); or thiazolyl, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have suitable substituent(s); R<sup>2</sup> is lower alkyl, lower alkoxy(lower)alkyl, cycloalkyl, ar(lower)alkyl which may have suitable substituent(s), heterocyclic group or heterocyclic(lower)alkyl, R<sup>3</sup> is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), and n is 0 or 1, and a pharmaceutically acceptable salt thereof which are useful as a medicament in the treatment of hypercholesterolemia, hyperlipidemia and atherosclerosis.




WO 96/10559

PCT/JP95/01982

- 210 -


## C L A I M S

1. A compound of the formula :



wherein

$\text{R}^1$  is a group of the formula :



(in which

$\text{R}^4$  is aryl which may have suitable substituent(s), or heterocyclic group which may have suitable substituent(s), and

Y is bond, lower alkylene, -S-, -O-,  $\overset{\text{C}}{\parallel}$ -C-,  
 =CH-, -CONH-, -N-CO-, (in which  $\text{R}^7$  is lower alkyl),  
 $\text{R}^7$   
 -NHSO<sub>2</sub>-, -SO<sub>2</sub>NH-, -SO<sub>2</sub>NHCO- or -CONHSO<sub>2</sub>-);  
 or

thiazolyl, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have suitable substituent(s);

$\text{R}^2$  is lower alkyl, lower alkoxy(lower)alkyl, cycloalkyl, ar(lower)alkyl which may have suitable substituent(s), heterocyclic group or heterocyclic(lower)alkyl,

$\text{R}^3$  is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable


WO 96/10559

PCT/JP95/01982

- 211 -

substituent(s), and  
n is 0 or 1,  
and a pharmaceutically acceptable salt thereof.

2. A compound of claim 1, wherein  
R<sup>1</sup> is a group of the formula :



(in which

R<sup>4</sup> is phenyl which may have 1 to 3 substituent(s)  
selected from the group consisting of  
halogen, lower alkyl, di(lower)alkylamino,  
protected amino, cyano, heterocyclic group  
which may have mono(or di or tri)-  
ar(lower)alkyl, hydroxy, protected hydroxy  
and mono(or di or tri)halo(lower)alkyl;  
or thienyl, pyrazolyl, imidazolyl,  
triazolyl, pyridyl, pyrrolyl, tetrazolyl,  
oxazolyl, thiazolyl, oxadiazolyl,  
piperazinyl, thiazolidinyl or  
methylenedioxyphenyl, each of which may have  
1 to 3 substituent(s) selected from the  
group consisting of lower alkyl, mono(or di  
or tri)ar(lower)alkyl and oxo;

Y is bond, lower alkylene, -S-, -O-, -C(=O)-, =CH-,  
-CONH-, -N-CO- (in which R<sup>7</sup> is lower alkyl),  
-NHSO<sub>2</sub>-, -SO<sub>2</sub>NH-, -SO<sub>2</sub>NHCO- or -CONHSO<sub>2</sub>-);  
or

thiazolyl, imidazolyl, pyrazolyl, pyridyl,